ELITE PHARMACEUTICALS INC /NV/ Quarterly Cost of Revenue in USD from Q2 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly/annual Cost of Revenue history and growth rate from Q2 2010 to Q2 2024.
  • Elite Pharmaceuticals Inc /Nv/ Cost of Revenue for the quarter ending June 30, 2024 was $10.3M, a 144% increase year-over-year.
  • Elite Pharmaceuticals Inc /Nv/ Cost of Revenue for the twelve months ending June 30, 2024 was $36.4M, a 101% increase year-over-year.
  • Elite Pharmaceuticals Inc /Nv/ annual Cost of Revenue for 2023 was $30.3M, a 72.4% increase from 2022.
  • Elite Pharmaceuticals Inc /Nv/ annual Cost of Revenue for 2022 was $17.6M, a 0.54% increase from 2021.
  • Elite Pharmaceuticals Inc /Nv/ annual Cost of Revenue for 2021 was $17.5M, a 29.3% increase from 2020.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $36.4M $10.3M +$6.1M +144% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $30.3M $9.83M +$5.04M +105% Jan 1, 2024 Mar 31, 2024 10-K 2024-07-01
Q4 2023 $25.2M $8.5M +$4.17M +96.2% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-14
Q3 2023 $21.1M $7.71M +$2.95M +61.9% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $18.1M $4.23M +$554K +15.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $17.6M $4.79M +$578K +13.7% Jan 1, 2023 Mar 31, 2023 10-K 2024-07-01
Q4 2022 $17M $4.33M -$626K -12.6% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 $17.6M $4.76M -$29K -0.61% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $17.6M $3.68M +$172K +4.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $17.5M $4.22M +$1.69M +66.7% Jan 1, 2022 Mar 31, 2022 10-K 2023-06-29
Q4 2021 $15.8M $4.96M +$2.31M +87.5% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 $13.5M $4.79M +$1.01M +26.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $12.5M $3.5M -$1.06M -23.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $13.5M $2.53M +$43.7K +1.76% Jan 1, 2021 Mar 31, 2021 10-K 2022-06-29
Q4 2020 $13.5M $2.64M +$480K +22.2% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 $13M $3.78M +$472K +14.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $12.5M $4.56M +$2.5M +121% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $10M $2.49M +$1.68M +207% Jan 1, 2020 Mar 31, 2020 10-K 2021-06-14
Q4 2019 $8.34M $2.16M +$392K +22.1% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-16
Q3 2019 $7.95M $3.31M +$2.76M +509% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 $5.18M $2.06M +$484K +30.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 $4.7M $811K +$350K +75.9% Jan 1, 2019 Mar 31, 2019 10-K 2020-06-30
Q4 2018 $4.35M $1.77M +$351K +24.7% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-10
Q3 2018 $4M $543K -$72.4K -11.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $4.07M $1.58M +$561K +55.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $3.51M $461K +$289K +168% Jan 1, 2018 Mar 31, 2018 10-K 2018-06-14
Q4 2017 $3.22M $1.42M -$307K -17.8% Oct 1, 2017 Dec 31, 2017 10-Q 2019-02-11
Q3 2017 $3.53M $615K -$1.24M -66.8% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 $4.77M $1.02M -$1.13M -52.7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $5.9M $172K -$864K -83.4% Jan 1, 2017 Mar 31, 2017 10-K 2018-06-14
Q4 2016 $6.76M $1.73M +$891K +107% Oct 1, 2016 Dec 31, 2016 10-K 2018-06-14
Q3 2016 $5.87M $1.85M +$436K +30.8% Jul 1, 2016 Sep 30, 2016 10-K 2018-06-14
Q2 2016 $5.44M $2.15M +$951K +79.4% Apr 1, 2016 Jun 30, 2016 10-K 2018-06-14
Q1 2016 $4.48M $1.04M +$132K +14.6% Jan 1, 2016 Mar 31, 2016 10-K 2018-06-14
Q4 2015 $4.35M $836K +$136K +19.4% Oct 1, 2015 Dec 31, 2015 10-K 2018-06-14
Q3 2015 $4.22M $1.42M +$733K +107% Jul 1, 2015 Sep 30, 2015 10-K 2018-06-14
Q2 2015 $3.48M $1.2M +$468K +64.2% Apr 1, 2015 Jun 30, 2015 10-K 2018-06-14
Q1 2015 $3.02M $904K -$142K -13.6% Jan 1, 2015 Mar 31, 2015 10-K 2017-06-14
Q4 2014 $3.16M $700K -$295K -29.6% Oct 1, 2014 Dec 31, 2014 10-K 2017-06-14
Q3 2014 $3.45M $682K +$65K +10.5% Jul 1, 2014 Sep 30, 2014 10-K 2017-06-14
Q2 2014 $3.39M $729K +$150K +25.9% Apr 1, 2014 Jun 30, 2014 10-K 2017-06-14
Q1 2014 $3.24M $1.05M -$68.4K -6.14% Jan 1, 2014 Mar 31, 2014 10-K 2016-06-15
Q4 2013 $3.31M $995K +$728K +273% Oct 1, 2013 Dec 31, 2013 10-K 2016-06-15
Q3 2013 $2.58M $617K +$137K +28.6% Jul 1, 2013 Sep 30, 2013 10-K 2016-06-15
Q2 2013 $2.44M $579K +$125K +27.4% Apr 1, 2013 Jun 30, 2013 10-K 2016-06-15
Q1 2013 $2.32M $1.11M +$759K +214% Jan 1, 2013 Mar 31, 2013 10-K 2014-06-30
Q4 2012 $1.56M $267K +$110K +70.4% Oct 1, 2012 Dec 31, 2012 10-Q 2014-02-14
Q3 2012 $1.45M $480K +$403K +528% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-14
Q2 2012 $1.04M $454K +$29K +6.82% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-14
Q1 2012 $1.01M $355K -$701K -66.4% Jan 1, 2012 Mar 31, 2012 10-K 2013-06-21
Q4 2011 $1.71M $157K -$485K -75.6% Oct 1, 2011 Dec 31, 2011 10-Q 2013-02-14
Q3 2011 $2.2M $76.3K -$489K -86.5% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-14
Q2 2011 $2.69M $425K +$13.7K +3.33% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-14
Q1 2011 $2.68M $1.06M Jan 1, 2011 Mar 31, 2011 10-K 2012-06-29
Q4 2010 $642K Oct 1, 2010 Dec 31, 2010 10-Q 2012-02-14
Q3 2010 $566K Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-14
Q2 2010 $412K Apr 1, 2010 Jun 30, 2010 10-Q/A 2011-08-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.